NCT06823479View on ClinicalTrials.gov

Towards Cure Via Only Ultra-short ICB in CSCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

May 14, 2025

Primary Completion Date

February 28, 2029

Study Completion Date

February 28, 2029

Conditions
Cutaneous Squamous Cell Carcinoma (CSCC)Cutaneous Squamous Cell CancerCutaneous Squamous Cell Carcinoma of the Head and NeckCutaneous Squamous Cell Carcinoma
Interventions
DRUG

Nivolumab

3 mg/kg

DRUG

Ipilumimab

1 mg/kg

Trial Locations (5)

6229HX

NOT_YET_RECRUITING

Maastricht UMC, Maastricht

1066CX

RECRUITING

Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam

1105AZ

NOT_YET_RECRUITING

Amsterdam UMC, Amsterdam

3015GD

NOT_YET_RECRUITING

Erasmus MC, Rotterdam

3584CX

NOT_YET_RECRUITING

UMC Utrecht, Utrecht

Sponsors

Collaborators (1)

Erasmus Medical Center
All Listed Sponsors
collaborator

UMC Utrecht

OTHER

collaborator

Erasmus Medical Center

OTHER

collaborator

Maastricht University Medical Center

OTHER

collaborator

Amsterdam UMC, location VUmc

OTHER

lead

The Netherlands Cancer Institute

OTHER